Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients

Table 5 Multivariate binary logistic regression for the use of ACEIs/ARBs, β-blockers, and MRAs in heart failure with reduced ejection fraction (EF < 40) patients

Variables	B	Sig	Exp (B)	95% CI for Exp (B)
Variables	B	Sig	Exp (B)	Lower	Upper
ACEIs/ARBs in heart failure with reduced ejection fraction
Age	− .033	.010	.968	.944	.992
Last clinic SBP	.020	.020	1.020	1.003	1.037
Anemia	− .707	.024	.493	.267	.910
CRF	− 1.228	.000	.293	.174	.492
Gout	− .613	.044	.542	.298	.983
GORD	− .602	.033	.548	.315	.952
MTD of ACEIs/ARBs in heart failure with reduced ejection fraction
Age	− .032	.000	.968	.952	.984
CRF	− .602	.010	.548	.346	.867
β-blockers in heart failure with reduced ejection fraction
Last clinic HR	− .028	.007	.973	.953	.992
Gout	− .891	.013	.410	.203	.828
IHD	.583	.048	1.792	1.006	3.191
MTD of β-blockers in heart failure with reduced ejection fraction
Age	− .040	.000	.961	.943	.979
Last clinic HR	− .026	.003	.974	.958	.991
MRAs use in heart failure with reduced ejection fraction
Age	− .040	.000	.960	.942	.979
Last clinic SBP	− .034	.000	.966	.955	.978

Variable (s) entered on step 1: last clinic SBP, last clinic DBP, any anemia, CRF, gout, IHD, GORD, any solid cancer, any CVA, PVD, OA, falls, any cognitive impairment, COPD, AF and any thyroid
EF, ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRF, chronic renal failure; IHD, ischemic heart diseases; GORD, gastroesophageal reflux diseases; CVA, cardiovascular accident; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary diseases; AF, atrial fibrillation; ACEIs/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor antagonists; MTD, maximum tolerated dose; MRAs, mineralocorticoid receptor blockers; HR, heart rate; COPD, chronic obstructive pulmonary diseases. p < .05 is considered significant
Only the significant variables in multivariate analysis are shown

ISSN: 1471-2261